REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...
Consistent Trophoblast Cell Surface Antigen 2 Positivity in Tracheobronchial Adenoid Cystic Carcinoma: Expanding Antibody-Drug Conjugate Opportunities in Rare Thoracic Tumor We conducted a ...
A discovery by a three-member Albert Einstein College of Medicine research team may boost the effectiveness of stem-cell transplants, commonly used for patients with cancer, blood disorders, or ...
TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology ...
BioAdaptives detailed the strategy behind its Xcellara platform, combining stem cell mobilization with tissue-targeting technology as it prepares to launch XcellaraHeart on August 1, 2026. Key ...
InvestorsHub on MSN
BioAdaptives announces XcellaraHeart cardiovascular wellness formula ahead of August launch
BioAdaptives has introduced XcellaraHeart™, a new cardiovascular wellness supplement built on its Xcellara™ platform, with commercial availability scheduled to begin on August 1, 2026. Key Investor ...
BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results